Cyclo Therapeutics, Inc. (CYTH) Misses Q2 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
- GoPro to merge with Starman Optical in $285M recapitalization deal
- GoPro (GPRO) Halted, News Pending
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Gap taps Coach architect Reed Krakoff for $29.95-$498 handbag line
- Comstock Resources signs $1.65B deal with SOCAR, $450M JV
Cyclo Therapeutics Provides Business Update and Reports Second Quarter 2022 Financial Results
August 16, 2022 8:05 AM EDTOn track to commence Phase 2 study of Trappsol® Cyclo for the treatment of Alzheimers Disease before year end
Continued execution on advancement of lead development program evaluating Trappsol® Cyclo for Niemann-Pick Disease Type C1 (NPC1) in ongoing global pivotal study (TransportNPC)
GAINESVILLE, Fla.--(BUSINESS WIRE)-- Cyclo Therapeutics, Inc. (Nasdaq:... More
